Bionano Genomics Expands Commercial Leadership Team to Accelerate Growth of Saphyr® and Bolster Customer Support and Experience Globally
“We are very impressed with the quality of talent we have recruited into our organization,” said
Amanda Lettmann joins Bionano after holding global enterprise leadership positions at Dexcom, Adobe Systems andDell /EMC . With her expertise in customer experience operations, business and digital transformation, and omnichannel engagement strategy and contributing to these companies becoming global leaders at scale, she will help lead Bionano’s global care, solutions and experiences teams to focus on customer innovation and centricity across the Company.Amanda Hernandez has over 15 years of experience selling multiple products and services within the pharmaceutical and medical diagnostics industries, most recently at Progenity. A Registered Nurse by training, she has exceled at connecting the right pieces in the commercial process to help create successful outcomes. Amanda is an accomplished leader who helps sales teams improve their selling skills to take their performance to the next level.Justin Leighton , a veteran in the genetics diagnostic testing industry, joins Bionano’sLineagen business, which focuses on clinical testing in pediatrics. He is a commercial leader in the industry with a diverse background in marketing, operations, IT and commercial matters, most recently at PerkinElmer. Justin has P&L responsibility forLineagen and will play a key role in helping Bionano work towards its goals in clinical applications.Bob Hertsenberg , a seasoned leader with sales leadership experience at HemoSonics, Cardio Dx andLipoScience , will focus on creating dynamic cross-functional teams to drive top-line revenue growth. Bob has built successful sales teams to drive sales revenue, but more importantly, to provide high levels of care for the patients and clients they serve. He will leverage his previous sales leadership experiences in the medical device and diagnostic industries and work to create a culture of innovation and ownership in the North American sales team.
“I am delighted to have Amanda, Amanda, Justin and Bob join the
About
Bionano is a genome analysis company providing tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing; it also provides diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the impact of the expansion of our commercial leadership team, including our expectations regarding the growth of Saphyr® and our ability to bolster customer support and experience globally. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; our hiring efforts may not achieve the anticipated results; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Media Relations:
Seismic
+1 (503) 799-7520
michael@teamseismic.com
Source: Bionano Genomics